These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 18272666)

  • 1. Immunization with a Pseudomonas aeruginosa 1244 pilin provides O-antigen-specific protection.
    Horzempa J; Held TK; Cross AS; Furst D; Qutyan M; Neely AN; Castric P
    Clin Vaccine Immunol; 2008 Apr; 15(4):590-7. PubMed ID: 18272666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal vaccination with a multivalent, live-attenuated vaccine induces multifactorial immunity against Pseudomonas aeruginosa acute lung infection.
    Kamei A; Coutinho-Sledge YS; Goldberg JB; Priebe GP; Pier GB
    Infect Immun; 2011 Mar; 79(3):1289-99. PubMed ID: 21149583
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Animal protection and structural studies of a consensus sequence vaccine targeting the receptor binding domain of the type IV pilus of Pseudomonas aeruginosa.
    Kao DJ; Churchill ME; Irvin RT; Hodges RS
    J Mol Biol; 2007 Nov; 374(2):426-42. PubMed ID: 17936788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-17 is a critical component of vaccine-induced protection against lung infection by lipopolysaccharide-heterologous strains of Pseudomonas aeruginosa.
    Priebe GP; Walsh RL; Cederroth TA; Kamei A; Coutinho-Sledge YS; Goldberg JB; Pier GB
    J Immunol; 2008 Oct; 181(7):4965-75. PubMed ID: 18802100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of an anti-adhesive vaccine for Pseudomonas aeruginosa targeting the C-terminal region of the pilin structural protein.
    Sheth HB; Glasier LM; Ellert NW; Cachia P; Kohn W; Lee KK; Paranchych W; Hodges RS; Irvin RT
    Biomed Pept Proteins Nucleic Acids; 1995; 1(3):141-8. PubMed ID: 9346845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of pilin protein with alum+naloxone adjuvant against acute pulmonary Pseudomonas aeruginosa infection.
    Banadkoki AZ; Keshavarzmehr M; Afshar Z; Aleyasin N; Fatemi MJ; Behrouz B; Hashemi FB
    Biologicals; 2016 Sep; 44(5):367-73. PubMed ID: 27427517
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advantages of a synthetic peptide immunogen over a protein immunogen in the development of an anti-pilus vaccine for Pseudomonas aeruginosa.
    Kao DJ; Hodges RS
    Chem Biol Drug Des; 2009 Jul; 74(1):33-42. PubMed ID: 19519742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pilin-based anti-Pseudomonas vaccines: latest developments and perspectives.
    Hahn H; Lane-Bell PM; Glasier LM; Nomellini JF; Bingle WH; Paranchych W; Smit J
    Behring Inst Mitt; 1997 Feb; (98):315-25. PubMed ID: 9382755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective distribution of Pseudomonas aeruginosa O-antigen among strains producing group I pilin.
    Allison TM; Castric P
    Pathog Dis; 2016 Feb; 74(1):ftv102. PubMed ID: 26527621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
    Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
    Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pseudomonas aeruginosa antigens as potential vaccines.
    Stanislavsky ES; Lam JS
    FEMS Microbiol Rev; 1997 Nov; 21(3):243-77. PubMed ID: 9451816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunopotentiation of the engineered low-molecular-weight pilin targeting Pseudomonas aeruginosa: A combination of immunoinformatics investigation and active immunization.
    Ahmadbeigi Y; Chirani AS; Soleimani N; Mahdavi M; Goudarzi M
    Mol Immunol; 2020 Aug; 124():70-82. PubMed ID: 32540517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycosylation of Pseudomonas aeruginosa 1244 pilin: glycan substrate specificity.
    DiGiandomenico A; Matewish MJ; Bisaillon A; Stehle JR; Lam JS; Castric P
    Mol Microbiol; 2002 Oct; 46(2):519-30. PubMed ID: 12406226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type IV pilus glycosylation mediates resistance of Pseudomonas aeruginosa to opsonic activities of the pulmonary surfactant protein A.
    Tan RM; Kuang Z; Hao Y; Lee F; Lee T; Lee RJ; Lau GW
    Infect Immun; 2015 Apr; 83(4):1339-46. PubMed ID: 25605768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of pilin glycosylation on Pseudomonas aeruginosa 1244 pilus function.
    Smedley JG; Jewell E; Roguskie J; Horzempa J; Syboldt A; Stolz DB; Castric P
    Infect Immun; 2005 Dec; 73(12):7922-31. PubMed ID: 16299283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Flagellin and pilin immunization against multi-drug resistant Pseudomonas aeruginosa protects mice in the burn wound sepsis model.
    Korpi F; Hashemi FB; Irajian G; Fatemi MJ; Laghaei P; Behrouz B
    Immunol Lett; 2016 Aug; 176():8-17. PubMed ID: 27210422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of a conjugate vaccine containing polymannuronic acid and flagellin against experimental Pseudomonas aeruginosa lung infection in mice.
    Campodónico VL; Llosa NJ; Bentancor LV; Maira-Litran T; Pier GB
    Infect Immun; 2011 Aug; 79(8):3455-64. PubMed ID: 21628521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthetic peptide vaccine development: designing dual epitopes into a single pilin peptide immunogen generates antibody cross-reactivity between two strains of Pseudomonas aeruginosa.
    Hackbarth C; Hodges RS
    Chem Biol Drug Des; 2010 Oct; 76(4):293-304. PubMed ID: 20807222
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.